Resources

Press Releases

GenomOncology Enables Novel Decision Support for Acute Myeloid Leukemia at the Nashville Veterans Affairs Hospital

CLEVELAND, Nov. 28, 2018 /PRNewswire/ -- GenomOncology LLC, a leading provider of end-to-end precision medicine solutions in oncology, has developed a solution to integrate IHC, FISH, NGS and Karyotyping in order to provide therapy and clinical trial recommendations. This innovative work was done in partnership with Vanderbilt University Medical Center, the Vanderbilt Ingram Cancer Center and the Nashville Veterans Affairs Hospital where it will be implemented. MORE

GenomOncology announces partnership with Indiana University School of Medicine

CLEVELAND, Nov. 13, 2018 /PRNewswire/ -- GenomOncology, LLC (GO) announced today that it was selected by the Indiana University School of Medicine to utilize GO's proprietary match algorithm and GO's extensive Knowledge Management System (KMS) application programming interface (API) suite to provide real-time clinical trial recommendations to clinical researchers for the benefit of IU patients. MORE

GenomOncology announces GO Pathology Workbench in use by Emory Healthcare for Clinical Reporting

CLEVELAND, Oct. 23, 2018 /PRNewswire/ -- GenomOncology today announced that Emory Healthcare is now using GenomOncology's GO Pathology Workbench system as part of its clinical reporting process, enabling the return of clinical reports to ordering physicians more rapidly and in a comprehensive format that aids their decision making. MORE

GenomOncology Adds Jonathan Seaton, Former SVP Corporate & Business Development at Illumina, to its Board of Directors

CLEVELAND, Sept. 25, 2018 -- GenomOncology LLC, a leading provider of end-to-end precision medicine solutions in oncology, has added Jonathan Seaton most recently Senior Vice President for Corporate & Business Development at Illumina to its Board of Directors. MORE

Fluidigm Partners with GenomOncology to Provide a Comprehensive Immuno-Oncology Gene Expression Solution on Biomark HD

Providing a best-in-class solution for immuno-oncology research, from RNA extraction to comprehensive data analysis, to advance therapeutic development MORE

UNMC, GenomOncology combine to launch the first system using HL7 2.5 formatting to transmit discrete genetic data on cancer patients to electronic health record

Breakthrough addresses huge problem in management of health information; will advance ability of health professionals to practice precision medicine and ensure patients receive right treatment at right time... MORE

GenomOncology Announces Working with Personalis to Improve Clinical Cancer Reporting Using GO Pathology Workbench

CLEVELAND, March 14, 2018


GenomOncology today announced that Personalis is now using the GO Pathology Workbench system as part of their clinical cancer reporting process, enabling return of clinical cancer reports to ordering physicians more rapidly and in an intuitive format that aids their decision making... MORE

UCSF Enhances Cancer Assay with Interpretive Reporting Powered by GenomOncology’s GO Clinical Workbench

CLEVELAND, June 27, 2017 (GLOBE NEWSWIRE) — GenomOncology today announced that UC San Francisco (UCSF) is now utilizing the GO Clinical Workbench for rapid analysis and reporting of results from the “UCSF500,” an advanced next-generation sequencing panel used by researchers and physicians... MORE

AACR Project GENIE: Powering Precision Medicine through an International Consortium

June 1, 2017

AACR published a research article outlining the GENIE project. We’re proud to share that GenomOncology team members, Clinton Miller, and Ian Mauer are listed as authors. This paper describes how GenomOncology leveraged the Knowledge Management System to load all ~19,000 GENIE cases to produce and verify several different figures. Since the KMS is loaded with clinical content, including My Cancer Genome content, professional guidelines, and clinical trials, GenomOncology was able to provide queries by “actionability”. VIEW PAPER

GenomOncology and med fusion announce the addition of PD-L1 Testing and Interpretation to the LungSEQ® and 50SEQ® Plus FISH Tests

CLEVELAND, March 06, 2017 (GLOBE NEWSWIRE) — med fusion, a Texas Oncology and The US Oncology Network preferred laboratory, and GenomOncology announce the expansion of med fusion’s LungSEQ® and 50SEQ® Plus FISH (for NSCLC) laboratory services to include PD-L1 expression testing. The panels will now help guide treatment selection of immunotherapeutic checkpoint inhibitors for… MORE

AGBT 2017: Knowledge-Enabled Workflow For Virtual Molecular Tumor Board

Adoption of molecular tumor profiling via next generation sequencing (NGS) is on the rise due to decreased cost and improved clinical actionability. However, due to high volume of information and guideline complexity, difficulty in accurate interpretation of molecular testing results persists. Virtual multidisciplinary molecular tumor conferences... MORE

AGBT 2017: Analysis Of Therapy And Trial Recommendations Based On Gene Panel Size

Panels of various sizes exist for NGS analysis of tumor samples. However, not much is known regarding the panel size that represents the best choice for specific cancer types. Therapeutic goal of NGS sequencing is to facilitate therapy and clinical trial identification based on a patient’s specific mutation profile. GenomOncology’s proprietary Match... MORE

Fluidigm and GenomOncology Partner To Provide Automated Oncology NGS Library Preparation With Molecular Interpretation And Reporting

SOUTH SAN FRANCISCO, Calif., Nov 8, 2016 – Fluidigm Corporation (NASDAQ:FLDM) and GenomOncology today announced a distribution agreement to co-market the GO Clinical Workbench™ for molecular interpretation of somatic variants identified using Fluidigm systems. An elegant solution for clinical research laboratories seeking accuracy, flexibility, and… MORE

GenomOncology Enhances the GO Clinical Workbench for Hematological Cancer Analysis and Reporting

CLEVELAND, Oct. 7, 2016 — GenomOncology today announced the recent extension of the GO Clinical Workbench™ to support Hematologic cancer testing and decision support. Molecular diagnostic laboratories across the country have used GenomOncology’s workbench for their solid tumor testing needs for over two years. GenomOncology’s clients have recently begun to validate and launch Hematologic malignancy… MORE

Updates to GenomOncology’s Platform Expand Company’s Footprint in Clinical NGS Market

Sep 27, 2016 | Uduak Grace Thomas

NEW YORK (GenomeWeb) – In the two years since it launched proprietary software solutions for next-generation sequence data analysis, GenomOncology has expanded its platform to include a number of additional applications that cater to a much broader range of analysis and interpretation needs. VIEW ARTICLE

Enhanced Biomarker-Based Clinical Trials Matching — Advances in Genome Biology and Technology (AGBT)

September 22-24, 2016

Identifying candidates for enrollment in clinical trials with biomarker-based eligibility criteria is a complex and data analysis-intensive task. Surprisingly, it has been estimated that ~60-95% of eligible patients go unidentified; for patients this means a missed opportunity at a potential cure, and for the drug approval system, a huge loss of time and resources.



To solve this problem, GenomOncology has developed a custom clinical trial curation tool used by the team at My Cancer Genome (MCG) to curate biomarker-based and disease-type eligibility criteria, which is party of our Knowledge Management System (KMS). The result of this process is a database where each clinical trial exists as a set of content based assertions, that interacts with the GO Clinical Workbench, in which patients with particular alterations and disease combinations are matched to the appropriate clinical trials in the most accurate manner possible. VIEW PDF

AMP 2016: Multi-Institution Comparison of PGM Panels Based on MolDx Technical Specifications

Analytical performance determination is a critical step in the development of a clinical assay. Some organizations, such as Palmetto GBA’s MolDx pro- gram, have established analytical performance char- acteristics that assays must meet. The present study investigates the analytical performance of a common 50 gene hotspot panel across multiple institutions using MolDx guidelines. Clinton Miller, Director of Bioinformatics at GenomOncology, presented this poster at AMP 2016. VIEW PDF

Genomics England to use GenomOncology’s Knowledge Management System to Analyze Cancer Samples in the 100,000 Genomes Project

Genomics England is partnering with GenomOncology, LLC (GO) to utilize the GO Knowledge Management System (GO KMS) as a tool for clinical reporting enablement.
Genomics England will integrate the GO KMS as a key content driver to augment clinical reporting in the 100,000 Genomes Project’s cancer programme, coupling Genomics England curated database with the GO... MORE

Pathline Emerge Launches DNA Profiling Tests using GenomOncology’s GO Clinical Workbench

July 12, 2016 CLEVELAND – GenomOncology today announced that Pathline Emerge recently went live with the GO Clinical Workbench for rapid analysis and reporting of their next-generation sequencing tests.


“Pathline Emerge takes a multi-disciplinary approach to evaluate specific types of cancer to support personalized medicine. Our full-service pathology laboratory was one of the first to obtain… MORE

Impact of Pre-Analytical Variables on Cancer Targeted Gene Sequencing Efficiency.

Tumor specimens are often preserved as formalin-fixed paraffin-embedded (FFPE) tissue blocks, the most common clinical source for DNA sequencing. Herein, we evaluated the effect of pre-sequencing parameters to guide proper sample selection for targeted gene sequencing. Data from 113 FFPE lung tumor specimens were collected, and targeted gene sequencing... VIEW PAPER

Congenica and GenomOncology announce collaborative agreement at AMP

November 5, 2015


CAMBRIDGE UK and CLEVELAND USA – Congenica, leader in genomic interpretation and diagnostics in rare genetic disease, and GenomOncology, specialists in precision medicine technology in the field of oncology, are announcing a pilot collaboration that will support the commercialisation of each other’s products in the USA and UK respectively and offer strategic… MORE

UCLA Health Implements Tumor DNA Profiling using GenomOncology’s GO Clinical Workbench

October 13, 2015 CLEVELAND – GenomOncology today announced that UCLA Health has adopted the GO Clinical WorkbenchTM to accelerate analysis and reporting for its tumor DNA profiling tests.


UCLA Health uses next generation sequencing for tumor profiling of its lung and colorectal cancer patients and has seen increasing demand for these treatment-guiding tests. Implementing and managing next… MORE

Multi-modal Report Summary for AML: Combining NGS and Cytogenetics Data to Enable Therapeutic Decision Making — American Society of Human Genetics Meeting

October 7, 2015


Acute myeloid leukemia (AML) is a clonal disorder of the blood forming cells characterized by accumulation of immature blast cells in the bone marrow and peripheral blood. It is a heterogeneous disease, and as such, its molecular footprint varies. It is therefore important to test for key genetic biomarkers for both prognostic and treatment purposes. Choice of treatments can benefit from genetic marker based risk stratification. VIEW PDF

Standardized NGS-based Assay Validation: GO Validation Reporting Framework – Cancer Genome Consortium Meeting

August 3, 2015


Cancer panels use next generation sequencing (NGS) technology to identify clinically relevant variants in cancer-related genes in order to impact patient care. Validating cancer panels for clinical testing is challenging due to the large number of variant positions covered by the panels and the low variant allelic frequency (VAF) that is often present in somatic cancer. The goal of this project was to utilize GenomAnalytics (GenomOncology, Cleveland, OH) software to facilitate the clinical validation of a 50 cancer-gene NGS panel. VIEW PDF

Doctors look towards genetic mutations to tailor therapies for cancer patients

June 5, 2015 CLEVELAND, OH (WOIO) – Matching the patient with the right kind of cancer fighting Dr. Alissa Marr and other physicians no longer tell patients with advanced lung cancer, “Here’s the chemotherapy that everyone with lung cancer gets.”


Today, the Omaha oncologist said, doctors often check to see if the person has a genetic mutation that can be treated with a targeted therapy that can be less toxic and effective for a longer period… VIEW ARTICLE

The Ohio State University Launches NGS Cancer Panels using GenomOncology’s GO Clinical Workbench

November 11, 2014


CLEVELAND, OH – GenomOncology announced today that the Ohio State University, College of Medicine, Department Of Pathology will use the company’s GO Clinical WorkbenchTM to enable clinical reporting of mutations detected from next generation sequencing (NGS)... MORE

GenomOncology President and CEO Manuel Glynias to Present at the Cleveland Clinic’s 12th Annual Medical Innovation Summit

October 22, 2014


CLEVELAND, OH – GenomOncology today announced that Manuel Glynias, the company’s President and CEO, will be presenting a corporate overview at the Cleveland Clinic’s 2014 Medical Innovation Summit to be held October 26-29 in Cleveland, OH.... MORE

med fusion and GenomOncology Partner to Match Drug and Clinical Trial Options to Patient Tumors

October 8, 2014


LEWISVILLE, TX and CLEVELAND, OH – med fusion, an integrated molecular center of excellence and clinical trials service organization and GenomOncology, an Ohio based genomics technology and services provider, today announced a partnership to optimize treatment strategies based on the patient’s disease state and tumor profile. The companies believe.... MORE

GenomOncology CEO featured in Channel 19 Evening News during Breast Cancer Awareness Month

October 4, 2014


CLEVELAND, OH (WOIO) – Matching the patient with the right kind of cancer fighting drug, especially when it comes to clinical trials, can be challenging and can take up precious time. But now, there’s potentially life saving software for that. Manuel Glynias is a Harvard and Case Western Reserve University Educated Scientist whose own life has been touched by cancer. “My dad died of Melanoma at age 50. He was diagnosed in June and was gone by October. That was 1975,” says Glynias. Fueled by his desire to find a cure and save lives, Glynias’s company GenomOncology developed a breakthrough technology that... VIEW ARTICLE

GenomOncology Collaborates With Vanderbilt-Ingram Cancer Center for the Commercial Development of My Cancer Genome™ Tools

February 10, 2014


WESTLAKE, OH – GenomOncology and Vanderbilt-Ingram Cancer Center (VICC) today announced a partnership for the exclusive commercial development of a decision support tool based on My Cancer Genome™, an online precision cancer medicine knowledge resource for physicians, patients, caregivers and researchers... MORE



Schedule a demo